Ultragenyx Pharmaceutical Inc. (RARE) Stock Profile — Insider Trades & Financials

Revenue$207.3M

Net Income-$128.6M

EPS$-5.83

Market Cap$2.2B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Emil Kakkis

CEO & Executive Director

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Founded: 2010
Employees: 893
Headquarters: NOVATO, CA, United States
Website

⚡

Core Efficiency

ROE?

160.69%

ROA?

-8.39%

D/E Ratio?

-20.06

Op. Margin?

-54.65%

📊

Profitability Ratios

Net Margin?

-62.02%

Loading company sections...

Ultragenyx Pharmaceutical Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness